FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010330135> ?p ?o ?g. }

• W3010330135 endingPage "646" @default.
• W3010330135 startingPage "635" @default.
• W3010330135 abstract "Abstract Purpose The combination of targeting the CDK4/6 and estrogen receptor (ER) signaling pathways with palbociclib and fulvestrant is a proven therapeutic strategy for the treatment of ER-positive breast cancer. However, the poor physicochemical properties of fulvestrant require monthly intramuscular injections to patients, which limit the pharmacokinetic and pharmacodynamic activity of the compound. Therefore, an orally available compound that more rapidly reaches steady state may lead to a better clinical response in patients. Here, we report the identification of G1T48, a novel orally bioavailable, non-steroidal small molecule antagonist of ER. Methods The pharmacological effects and the antineoplastic mechanism of action of G1T48 on tumors was evaluated using human breast cancer cells (in vitro) and xenograft efficacy models (in vivo). Results G1T48 is a potent and efficacious inhibitor of estrogen-mediated transcription and proliferation in ER-positive breast cancer cells, similar to the pure antiestrogen fulvestrant. In addition, G1T48 can effectively suppress ER activity in multiple models of endocrine therapy resistance including those harboring ER mutations and growth factor activation. In vivo, G1T48 has robust antitumor activity in a model of estrogen-dependent breast cancer (MCF7) and significantly inhibited the growth of tamoxifen-resistant (TamR), long-term estrogen-deprived (LTED) and patient-derived xenograft tumors with an increased response being observed with the combination of G1T48 and the CDK4/6 inhibitor lerociclib. Conclusions These data show that G1T48 has the potential to be an efficacious oral antineoplastic agent in ER-positive breast cancer." @default.
• W3010330135 created "2020-03-13" @default.
• W3010330135 creator A5005296809 @default.
• W3010330135 creator A5011431837 @default.
• W3010330135 creator A5012103903 @default.
• W3010330135 creator A5020757036 @default.
• W3010330135 creator A5032831863 @default.
• W3010330135 creator A5033246654 @default.
• W3010330135 creator A5035365399 @default.
• W3010330135 creator A5037408779 @default.
• W3010330135 creator A5039526482 @default.
• W3010330135 creator A5043288910 @default.
• W3010330135 creator A5049308978 @default.
• W3010330135 creator A5055778912 @default.
• W3010330135 creator A5058971478 @default.
• W3010330135 creator A5061807616 @default.
• W3010330135 creator A5071271602 @default.
• W3010330135 creator A5076445644 @default.
• W3010330135 creator A5078598967 @default.
• W3010330135 creator A5085256589 @default.
• W3010330135 date "2020-03-04" @default.
• W3010330135 modified "2023-10-05" @default.
• W3010330135 title "G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer" @default.
• W3010330135 cites W1971749886 @default.
• W3010330135 cites W1980557732 @default.
• W3010330135 cites W1981476886 @default.
• W3010330135 cites W1991734968 @default.
• W3010330135 cites W1992533338 @default.
• W3010330135 cites W1997006452 @default.
• W3010330135 cites W2000328666 @default.
• W3010330135 cites W2004271648 @default.
• W3010330135 cites W2021145743 @default.
• W3010330135 cites W2048015102 @default.
• W3010330135 cites W2054372078 @default.
• W3010330135 cites W2056835200 @default.
• W3010330135 cites W2065958815 @default.
• W3010330135 cites W2073367400 @default.
• W3010330135 cites W2090629961 @default.
• W3010330135 cites W2098505104 @default.
• W3010330135 cites W2099493846 @default.
• W3010330135 cites W2102542135 @default.
• W3010330135 cites W2107277218 @default.
• W3010330135 cites W2107859602 @default.
• W3010330135 cites W2110997369 @default.
• W3010330135 cites W2111324624 @default.
• W3010330135 cites W2126773860 @default.
• W3010330135 cites W2128898940 @default.
• W3010330135 cites W2135944809 @default.
• W3010330135 cites W2142334766 @default.
• W3010330135 cites W2151463503 @default.
• W3010330135 cites W2163248521 @default.
• W3010330135 cites W2243467818 @default.
• W3010330135 cites W2258559299 @default.
• W3010330135 cites W2287060719 @default.
• W3010330135 cites W2290950904 @default.
• W3010330135 cites W2323968754 @default.
• W3010330135 cites W2332737325 @default.
• W3010330135 cites W2346465624 @default.
• W3010330135 cites W2411335118 @default.
• W3010330135 cites W2468302041 @default.
• W3010330135 cites W2511391150 @default.
• W3010330135 cites W2538138106 @default.
• W3010330135 cites W2565707423 @default.
• W3010330135 cites W2580935506 @default.
• W3010330135 cites W2588404810 @default.
• W3010330135 cites W2601079093 @default.
• W3010330135 cites W2611953519 @default.
• W3010330135 cites W2612084686 @default.
• W3010330135 cites W2619213753 @default.
• W3010330135 cites W2619858681 @default.
• W3010330135 cites W2620993107 @default.
• W3010330135 cites W2765643657 @default.
• W3010330135 cites W2775764871 @default.
• W3010330135 cites W2791894234 @default.
• W3010330135 cites W2794154000 @default.
• W3010330135 cites W2805575723 @default.
• W3010330135 cites W2889898143 @default.
• W3010330135 cites W2896846857 @default.
• W3010330135 cites W2904445846 @default.
• W3010330135 cites W2953561084 @default.
• W3010330135 cites W2964142306 @default.
• W3010330135 cites W2975211683 @default.
• W3010330135 cites W2977879417 @default.
• W3010330135 cites W779403461 @default.
• W3010330135 doi "https://doi.org/10.1007/s10549-020-05575-9" @default.
• W3010330135 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7103015" @default.
• W3010330135 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32130619" @default.
• W3010330135 hasPublicationYear "2020" @default.
• W3010330135 type Work @default.
• W3010330135 sameAs 3010330135 @default.
• W3010330135 citedByCount "30" @default.
• W3010330135 countsByYear W30103301352020 @default.
• W3010330135 countsByYear W30103301352021 @default.
• W3010330135 countsByYear W30103301352022 @default.
• W3010330135 countsByYear W30103301352023 @default.
• W3010330135 crossrefType "journal-article" @default.
• W3010330135 hasAuthorship W3010330135A5005296809 @default.
• W3010330135 hasAuthorship W3010330135A5011431837 @default.

• next